ArticleDiabetology & metabolic syndrome2015

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.

Shirong Qiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.